ArticleBMJ open2026

Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as treatment for HER2-expressing advanced urothelial cancer in China.

Yize Jia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.